Combined therapy with deferoxamine and deferiprone

Area of Science:

• Hematology
• Pharmacology
• Internal Medicine

Background:

• Iron chelation therapy with deferiprone (DFP) or deferoxamine (DFO) alone is often insufficient for thalassemia patients.
• Accumulating evidence suggests enhanced efficacy when combining DFP and DFO.

Purpose of the Study:

• To evaluate the efficacy and safety of combined iron chelation therapy using DFP and DFO in thalassemia patients.

Main Methods:

• Review of theoretical, experimental, and clinical data on combined DFP and DFO therapy.
• Analysis of iron-balance studies and long-term outcomes including ferritin levels, liver iron concentration, and cardiac siderosis.

Main Results:

• Combined DFP and DFO therapy, administered simultaneously or sequentially, effectively induces negative iron balance in all patients.
• Long-term combination therapy significantly reduces ferritin levels, liver iron, and improves cardiac siderosis and function.
• The regimen is well-tolerated and safe, with a manageable increase in agranulocytosis risk compared to DFP monotherapy.

Conclusions:

• Combining DFP and DFO provides a flexible and effective therapeutic strategy for managing iron overload in thalassemia.
• This approach offers personalized treatment options for patients with hemosiderosis.